Chembio Diagnostics
Chembio Diagnostics Q1 Revenues Climb 26 Percent on Government Grant Income
The firm said that in Q1 its product revenues fell 30 percent year over year to $4.0 million, but government grant income contributed $3.4 million to its revenues.
Chembio Diagnostics Shares Rise 60 Percent on Launch of SARS-CoV-2, Influenza Test
The firm said it has licensed an instrument-free rapid immunoassay from an undisclosed test manufacturer that has received FDA Emergency Use Authorization.
In Brief This Week: Grail, Illumina, Veracyte, Aspira Women's Health, and More
News items for the in vitro diagnostics industry for the week of March 15, 2021.
The firm plans to expand the menu for its immunoassay reader, anchoring its US expansion to a novel dual test for HIV and syphilis.
Chembio Q4 Revenues Jump 62 Percent, Beat EstimatesÂ
The firm recently in-licensed distribution of an Emergency Use Authorized SARS-CoV-2 antigen assay it expects to launch in March 2021.